

# Rosanna Tarricone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3358007/publications.pdf>

Version: 2024-02-01

119  
papers

3,670  
citations

126907

33  
h-index

149698

56  
g-index

124  
all docs

124  
docs citations

124  
times ranked

4827  
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms. <i>PharmacoEconomics - Open</i> , 2022, , 1.	1.8	0
2	How to Reduce Inequity of Access to Cardiac Rehabilitation After Surgical Aortic Valve Replacement. Recommendations for the Postâ€œCOVID-19 Era From a Real-World, Population-Based Study. <i>Clinical Therapeutics</i> , 2022, 44, 491-507.	2.5	3
3	European union regulation of health technology assessment: what is required for it to succeed?. <i>European Journal of Health Economics</i> , 2022, 23, 913-915.	2.8	6
4	Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps. <i>Health Economics (United Kingdom)</i> , 2022, 31, 73-97.	1.7	13
5	Recommendations for the design and implementation of an Early Feasibility Studies program for medical devices in the European Union. <i>Expert Review of Medical Devices</i> , 2022, 19, 315-325.	2.8	4
6	Endovascular versus surgical creation of arteriovenous fistula in hemodialysis patients: Cost-effectiveness and budget impact analyses. <i>Journal of Vascular Access</i> , 2021, 22, 48-57.	0.9	15
7	Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e62.	0.5	14
8	Distinguishing features in the assessment of mHealth apps. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 521-526.	1.4	32
9	Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies. <i>Health Policy</i> , 2021, 125, 602-608.	3.0	20
10	Investigating Patientsâ€™ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4916.	2.6	3
11	Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 35.	1.5	11
12	Clinical guidelines versus current clinical practice for the management of deep vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 1334-1344.e1.	1.6	7
13	Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials. <i>Npj Digital Medicine</i> , 2021, 4, 144.	10.9	24
14	The evolution of the Italian National Health Service. <i>Lancet, The</i> , 2021, 398, 2193-2206.	13.7	37
15	An Electronic Patient-Reported Outcome Mobile App for Data Collection in Type A Hemophilia: Design and Usability Study. <i>JMIR Formative Research</i> , 2021, 5, e25071.	1.4	5
16	Measuring Value in Health Care: A Comparative Analysis of Value-based Frameworks. <i>Clinical Therapeutics</i> , 2020, 42, 34-43.	2.5	18
17	Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis. <i>Value in Health</i> , 2020, 23, 17-24.	0.3	15
18	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <i>Expert Review of Medical Devices</i> , 2020, 17, 993-1006.	2.8	15

#	ARTICLE	IF	CITATIONS
19	Venous stenting for patients with outflow obstruction and leg ulcers: cost-effectiveness and budget impact analyses. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 705-720.	1.4	7
20	Impact of point of care ultrasound on the number of diagnostic examinations in elderly patients admitted to an internal medicine ward. <i>European Journal of Internal Medicine</i> , 2020, 79, 88-92.	2.2	14
21	The rise of rules: Will the new EU regulation of medical devices make us safer?. <i>European Journal of Internal Medicine</i> , 2020, 80, 117-120.	2.2	8
22	Should health technology assessment be more patient centric? If so, how?. <i>European Journal of Health Economics</i> , 2020, 21, 1117-1120.	2.8	11
23	Clinical outcomes and quality of life associated with the use of a biosynthetic mesh for complex ventral hernia repair: analysis of the Italian Hernia Club registry. <i>Scientific Reports</i> , 2020, 10, 10706.	3.3	28
24	A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis. <i>Pathogens</i> , 2020, 9, 502.	2.8	10
25	Cost-benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet. <i>Clinical Therapeutics</i> , 2020, 42, 60-75.e7.	2.5	8
26	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	2.7	9
27	What can health systems learn from COVID-19?. <i>European Heart Journal Supplements</i> , 2020, 22, P4-P8.	0.1	13
28	Harnessing Digital Health Technologies During and After the COVID-19 Pandemic: Context Matters. <i>Journal of Medical Internet Research</i> , 2020, 22, e21815.	4.3	45
29	Integrating HTA Principles into Procurement of Medical Devices: The Italian National HTA Programme for Medical Devices. <i>IFMBE Proceedings</i> , 2020, , 1777-1782.	0.3	0
30	Approccio value-based e logiche di finanziamento: implicazioni per le politiche di rimborsabilit� in sanit�. <i>Mecosan</i> , 2020, , 83-101.	0.1	0
31	Delivering Effective Care Through Mobile Apps: Findings from a Multi-stakeholder Design Science Approach. <i>Lecture Notes in Computer Science</i> , 2020, , 3-14.	1.3	1
32	&lt;p&gt;Impact of a probiotic-based hospital sanitation on antimicrobial resistance and HAI-associated antimicrobial consumption and costs: a multicenter study&lt;p&gt;. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 501-510.	2.7	43
33	Basic Principles of Health Technology Assessment, Economic Evaluation, and Costing of Healthcare Programs. , 2019, , 141-156.		0
34	Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. <i>European Journal of Health Economics</i> , 2019, 20, 181-193.	2.8	14
35	Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. <i>BMJ Open</i> , 2019, 9, e025483.	1.9	22
36	Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results From a Cross-Sectional International Survey. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13584.	3.7	19

#	ARTICLE	IF	CITATIONS
37	State-of-the-Art of Abdominal Wall Surgery in Italy: Coding, Reimbursement, Hospitalisations and Expenditure for Surgical Meshes. , 2019, , 87-104.		0
38	The impacts of diabetes research from 31 European Countries in 2002 to 2013. Research Evaluation, 2018, 27, 270-282.	2.6	6
39	Does the approach to economic evaluation in health care depend on culture, values, and institutional context?. European Journal of Health Economics, 2018, 19, 769-774.	2.8	25
40	Costâ€effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. Journal of Comparative Effectiveness Research, 2018, 7, 209-221.	1.4	5
41	Budget Impact Analysis of a Biosynthetic Mesh for Incisional Hernia Repair. Clinical Therapeutics, 2018, 40, 1830-1844.e4.	2.5	15
42	Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients. BMJ Open, 2018, 8, e022291.	1.9	5
43	Reducing healthcare-associated infections incidence by a probiotic-based sanitation system: A multicentre, prospective, intervention study. PLoS ONE, 2018, 13, e0199616.	2.5	57
44	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer, 2018, 18, 715.	2.6	15
45	Myth #5: Health Care Is Rightly Left to the Private Sector, for the Sake of Efficiency. , 2018, , 123-154.		2
46	La centralizzazione degli acquisti di dispositivi medici. Metodologia per l'analisi comparativa dei capitolati di gara. Mecosan, 2018, , 7-26.	0.1	1
47	Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value in Health, 2017, 20, 336-344.	0.3	29
48	Improving the Methods for the Economic Evaluation of Medical Devices. Health Economics (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.7	46
49	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. Health Economics (United Kingdom), 2017, 26, 109-123.	1.7	52
50	Foreword. Health Economics (United Kingdom), 2017, 26, 3-4.	1.7	0
51	Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urology, 2017, 17, 4.	1.4	61
52	Learning effect and diffusion of innovative medical devices: the case of transcatheter aortic valve implantation in Italy. Journal of Comparative Effectiveness Research, 2017, 6, 279-292.	1.4	7
53	Key Recommendations from the MedtechTA Project. Health Economics (United Kingdom), 2017, 26, 145-152.	1.7	44
54	Challenges in the Assessment of Medical Devices: The MedtechTA Project. Health Economics (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	60

#	ARTICLE	IF	CITATIONS
55	The impact of HTA and procurement practices on the selection and prices of medical devices. Social Science and Medicine, 2017, 174, 89-95.	3.8	32
56	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-SPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value in Health, 2017, 20, 1003-1008.	0.3	243
57	Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-SPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiology and Drug Safety, 2017, 26, 1033-1039.	1.9	251
58	European diabetes research and its funding, 2002-2013. Diabetic Medicine, 2017, 34, 1354-1360.	2.3	14
59	Healthcare resource consumption for intermittent urinary catheterisation: cost-effectiveness of hydrophilic catheters and budget impact analyses. BMJ Open, 2017, 7, e012360.	1.9	17
60	A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourology and Urodynamics, 2017, 36, 1178-1186.	1.5	49
61	PP100 Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections. International Journal of Technology Assessment in Health Care, 2017, 33, 118-119.	0.5	0
62	VP55 Health Technology Assessment Of Orphan Drugs: The Case Of Hereditary Angioedema In Italy. International Journal of Technology Assessment in Health Care, 2017, 33, 173-174.	0.5	0
63	OP60 Ramucirumab In Gastric Cancer Treatment: An Economic Evaluation. International Journal of Technology Assessment in Health Care, 2017, 33, 26-27.	0.5	0
64	PP149 Assessment Of New Medical Devices With Administrative Databases. International Journal of Technology Assessment in Health Care, 2017, 33, 139-140.	0.5	0
65	VP102 The Determinants Of Diffusion Of New Technologies Across Life Cycle. International Journal of Technology Assessment in Health Care, 2017, 33, 196-196.	0.5	0
66	Cost-effectiveness of timely versus delayed primary total hip replacement in Germany: A social health insurance perspective. Orthopedic Reviews, 2017, 9, 7161.	1.3	13
67	Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open, 2016, 6, e009669.	1.9	53
68	Current and Future Trends in the HTA of Medical Devices. IFMBE Proceedings, 2016, , 1345-1348.	0.3	6
69	Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation. International Journal of Cardiology, 2016, 209, 153-160.	1.7	37
70	What type of clinical evidence is needed to assess medical devices?. European Respiratory Review, 2016, 25, 259-265.	7.1	35
71	Incentivizing research into the effectiveness of medical devices. European Journal of Health Economics, 2016, 17, 1055-1058.	2.8	11
72	Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review. Health Policy, 2016, 120, 1-15.	3.0	44

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. <i>Clinical Drug Investigation</i> , 2016, 36, 177-194.	2.2	51
74	Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 49-62.	4.4	34
75	Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 13-36.	4.4	114
76	Comparing Drug and Nondrug Technologies in Comparative Effectiveness Research. , 2016, , 275-290.		1
77	A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 37-48.	4.4	27
78	De innovazione: The concept of innovation for medical technologies and its implications for healthcare policy-making. <i>Health Policy and Technology</i> , 2016, 5, 47-64.	2.5	38
79	Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 107-115.	1.9	71
80	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. <i>Oncotarget</i> , 2016, 7, 72343-72355.	1.8	57
81	Il governo dell'innovazione tecnologica in sanità. Il caso dell'impianto di valvola aortica transcateretere: stato dell'arte delle indicazioni e della rimborsabilità nelle regioni italiane. <i>Mecosan</i> , 2016, , 137-160.	0.1	0
82	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 1-3.	2.1	0
83	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117.	2.5	27
84	Comparing Drug and Non-drug Technologies in Comparative Effectiveness Research. , 2015, , 1-17.		0
85	Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review. <i>Expert Review of Medical Devices</i> , 2015, 12, 471-485.	2.8	3
86	Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project. <i>Pharmacoeconomics</i> , 2015, 33, 61-69.	3.3	52
87	Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 707-718.	1.4	36
88	Impatto del sistema di finanziamento a DRG sull'innovazione tecnologica in sanità. Il caso italiano. <i>Mecosan</i> , 2014, , 31-48.	0.1	2
89	Assessing the Added Value of Health Technologies: Reconciling Different Perspectives. <i>Value in Health</i> , 2013, 16, S7-S13.	0.3	64
90	Explaining the Health Costs Associated with Managing Intracranial Aneurysms in Italy. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 427-435.	2.1	1

#	ARTICLE	IF	CITATIONS
91	An Economic Perspective on Urinary Tract Infection: The “Costs of Resignation” Clinical Drug Investigation, 2013, 33, 255-261.	2.2	69
92	Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. Value in Health, 2013, 16, S4-S6.	0.3	5
93	Genetic Screening for the Predisposition to Venous Thromboembolism: A Cost-Utility Analysis of Clinical Practice in the Italian Health Care System. Value in Health, 2013, 16, 909-921.	0.3	14
94	Planning and control of medical device investments by Italian public health authorities: A means to improve the decision-making process. Journal of Medical Marketing, 2013, 13, 135-141.	0.2	3
95	The economic impact of a medical device company’s location in Italy. Journal of Medical Marketing, 2013, 13, 24-36.	0.2	2
96	The role of product life cycle in medical technology innovation. Journal of Medical Marketing, 2013, 13, 37-43.	0.2	14
97	Determinants of demand for total hip and knee arthroplasty: a systematic literature review. BMC Health Services Research, 2012, 12, 225.	2.2	114
98	Diffusion and use of health technology assessment in policy making: What lessons for decentralised healthcare systems?. Health Policy, 2012, 108, 194-202.	3.0	39
99	Economic evidence of interventions for acute myocardial infarction: a review of the literature. EuroIntervention, 2012, 8, P71-P76.	3.2	5
100	Pharmaco-economics and decision making in health care. The case of “extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis” Internal and Emergency Medicine, 2011, 6, 581-582.	2.0	0
101	Challenges in the clinical and economic evaluation of medical devices: The case of transcatheter aortic valve implantation. Journal of Medical Marketing, 2011, 11, 221-229.	0.2	16
102	Applying health economics for policy decision making: do devices differ from drugs?. Europace, 2011, 13, ii54-ii58.	1.7	40
103	Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Effectiveness and Resource Allocation, 2010, 8, 8.	1.5	40
104	Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review. Urology, 2010, 75, 491-500.	1.0	182
105	Economic Evaluation for Devices and Drugs “Same or Different?. Value in Health, 2009, 12, 402-404.	0.3	190
106	Analisi economica dei costi e dei benefici dell’implementazione di un programma di prevenzione antirotavirus con il vaccino pentavalente in Italia. Pharmacoconomics Italian Research Articles, 2009, 11, 1-13.	0.2	2
107	How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. Journal of Medical Economics, 2008, 11, 265-279.	2.1	6
108	Cost-effectiveness analysis for trigeminal neuralgia: Cyberknife vs microvascular decompression. Neuropsychiatric Disease and Treatment, 2008, 4, 647.	2.2	29

#	ARTICLE	IF	CITATIONS
109	Cost-of-illness analysis. Health Policy, 2006, 77, 51-63.	3.0	399
110	What do people think about disabled youth and employment in developed and developing countries? Results from an eâ€discussion hosted by the World Bank. Disability and Society, 2006, 21, 645-650.	2.2	10
111	The economic burden of stroke in Italy. The ECLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. Neurological Sciences, 2005, 26, 72-80.	1.9	45
112	Economic Evaluation of a New Antiemetic Drug ??? Palonosetron versus Ondansetron. Clinical Drug Investigation, 2005, 25, 597-608.	2.2	9
113	Oxaprozin versus diclofenac in NSAID-refractory periartthritis pain of the shoulder. Current Medical Research and Opinion, 2004, 20, 1279-1290.	1.9	19
114	What reimbursement for coronary revascularization with drug-eluting stents?. European Journal of Health Economics, 2004, 5, 309-316.	2.8	16
115	Economic evaluation of osteoarthritis treatment in Europe. Expert Opinion on Pharmacotherapy, 2003, 4, 327-341.	1.8	8
116	Economic Evaluation of Nimesulide versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain. Clinical Drug Investigation, 2001, 21, 453-464.	2.2	9
117	Valutazione di convenienza economica comparata tra quetiapina e risperidone nel trattamento della schizofrenia. Pharmacoeconomics Italian Research Articles, 2001, 3, 27-36.	0.2	3
118	Direct and indirect costs of schizophrenia in community psychiatric services in Italy. Health Policy, 2000, 51, 1-18.	3.0	61
119	The Costs of Pharmacological Treatment for Major Depression. Pharmacoeconomics, 2000, 17, 167-174.	3.3	8